Skip to main content

Single cell analysis of clonal heterogeneity in myelodysplastic syndromes treated with azacitidine

FJC2020-044658-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Juan de la Cierva Formación
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.